Awaiting development: Guidance and quality standards

Showing 11 to 20 of 373

Guidance and quality standards awaiting development
Title	Type
Advocacy services for adults with health and social care needs	Quality standard
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]	Technology appraisal guidance
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]	Technology appraisal guidance
AI technologies to aid the scoring and interpretation of diagnostic sleep studies	HealthTech guidance
AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735]	Technology appraisal guidance
Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754]	Technology appraisal guidance
Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]	Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]	Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664]	Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance